Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelica M Gutierrez-Barrera

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
International Journal of Oncology|May 16, 2015
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cellsBanu Arun, Ugur Akar, Angelica M Gutierrez-Barrera, et al.
Biochemical and Biophysical Research Communications|May 22, 2007
Establishment of three-dimensional cultures of human pancreatic duct epithelial cellsAngelica M Gutierrez-Barrera, David G Menter, James L Abbruzzese, et al.
Annals of Surgical Oncology|July 29, 2020
Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel TestingBrittany L Murphy, Min Yi, Banu K Arun, et al.
The Breast Journal|January 23, 2023
Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in <i>BRCA1/2</i>: Overall Survival, Racial, and Ethnic DifferencesSukh Makhnoon, Angelica M Gutierrez Barrera, Roland Bassett, et al.
Cancer Medicine|October 13, 2017
Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomesGustavo Schvartsman, Angelica M Gutierrez-Barrera, Juhee Song, et al.
Annals of Surgical Oncology|September 12, 2022
Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel TestingBrittany L Murphy, Min Yi, Angelica M Gutierrez Barrera, et al.
Cancer Medicine|February 7, 2022
Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancerRachel M Layman, Heather Lin, Angelica M Gutierrez Barrera, et al.
The Breast Journal|June 5, 2020
Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutationsSoley Bayraktar, Jade Z Zhou, Roland Bassett, et al.
Biomarkers in Cancer|September 2, 2015
Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast CancerSoley Bayraktar, Hongming Qiu, Diane Liu, et al.
Breast Cancer Research and Treatment|May 22, 2013
Simplifying clinical use of the genetic risk prediction model BRCAPROSwati Biswas, Philamer Atienza, Jonathan Chipman, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
International Journal of Oncology|May 16, 2015
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cellsBanu Arun, Ugur Akar, Angelica M Gutierrez-Barrera, et al.
Biochemical and Biophysical Research Communications|May 22, 2007
Establishment of three-dimensional cultures of human pancreatic duct epithelial cellsAngelica M Gutierrez-Barrera, David G Menter, James L Abbruzzese, et al.
Annals of Surgical Oncology|July 29, 2020
Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel TestingBrittany L Murphy, Min Yi, Banu K Arun, et al.
The Breast Journal|January 23, 2023
Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in <i>BRCA1/2</i>: Overall Survival, Racial, and Ethnic DifferencesSukh Makhnoon, Angelica M Gutierrez Barrera, Roland Bassett, et al.
Cancer Medicine|October 13, 2017
Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomesGustavo Schvartsman, Angelica M Gutierrez-Barrera, Juhee Song, et al.
Annals of Surgical Oncology|September 12, 2022
Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel TestingBrittany L Murphy, Min Yi, Angelica M Gutierrez Barrera, et al.
Cancer Medicine|February 7, 2022
Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancerRachel M Layman, Heather Lin, Angelica M Gutierrez Barrera, et al.
The Breast Journal|June 5, 2020
Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutationsSoley Bayraktar, Jade Z Zhou, Roland Bassett, et al.
Biomarkers in Cancer|September 2, 2015
Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast CancerSoley Bayraktar, Hongming Qiu, Diane Liu, et al.
Breast Cancer Research and Treatment|May 22, 2013
Simplifying clinical use of the genetic risk prediction model BRCAPROSwati Biswas, Philamer Atienza, Jonathan Chipman, et al.
Pageof 4